Resmed Inc. Stock
Resmed Inc. Stock
Resmed Inc. gained 0.510% compared to yesterday.
The stock is an absolute favorite of our community with 23 Buy predictions and no Sell predictions.
As a result the target price of 259 € shows a slightly positive potential of 19.35% compared to the current price of 217.0 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.510% | 3.877% | 0.930% | -4.991% | 4.077% | 8.783% | 19.231% |
| Thermo Fisher Scientific Inc. | 2.440% | 5.201% | 7.911% | 0.472% | 7.649% | -1.827% | 25.902% |
| Veeva Systems A | 0.770% | 10.222% | 5.627% | -2.915% | 7.833% | 34.353% | -12.832% |
| QuidelOrtho Corp. | 2.080% | 17.886% | 14.173% | -35.268% | 16.000% | -63.975% | -82.424% |
Comments
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?
ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.
